Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

Cidara submits new drug application for and licenses antifungal

by Shi En Kim
August 8, 2022 | A version of this story appeared in Volume 100, Issue 27

 

A structure of rezafungin.

After promising results from separate Phase 2 and 3 trials, Cidara Therapeutics has submitted a new drug application to the US Food and Drug Administration (FDA) for the compound rezafungin, for which the company expects a response in early 2023 if the FDA accepts the drug candidate for review. Designated as an orphan drug, the molecule aims to treat and prevent yeast infections in the bloodstream and among people undergoing blood or marrow transplantation. In a deal potentially worth $460 million, Cidara has also agreed to license rezafungin exclusively to Melinta Therapeutics for commercialization in the US.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.